N-Myc amplification, observed in about 25% of primary tumours, is strongly associated with rapid tumour progression and a poor outcome, independently from the stage of the tumour or the age of the patient, and has thus become an important factor in clinical decision-making and therapy (Brodeur, 2003). This evidence concerns the gene MYCN and neoplasm.